ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2024
Pulmonary rehabilitation in connective tissue disease-associated interstitial lung disease: A systematic review.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Improving Psychological Well-Being and Quality of Life in Rheumatoid Arthritis-Associated Interstitial Lung Disease Through Exercise and Pulmonary Rehabilitation: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Review
- Connective Tissue Disorder-Induced Diffuse Alveolar Hemorrhage: A Comprehensive Review with an Emphasis on Airway and Respiratory Management.Life (Basel, Switzerland) · 2025Review
- Factors affecting quality of life in connective tissue disease-related interstitial lung disease.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimInterstitial lung disease (ILD) is the major contributor to mortality in between chronic lung diseases. ILD originates from voluminous pathophysiological factors. One of the reasons is connective tissue diseases (CTD). According to experts, patients with CTD-ILD may have a stable disease activity and not need conventional treatment. Also, with pulmonary rehabilitation (PR), these patients may benefit from improving clinical outcomes and regression in mortality. However, the characteristics of these patients and whether they have stable disease activity in practice are not known.
methodsThe systematic review was performed via the AI-powered tool with six databases to conduct literature research. The methodologic quality of the studies, risk of bias, and level of evidence were assessed.
resultsAccording to the final four included studies PR benefit moderate levels of evidence for lung functions and diffusion capacity, functional capacity, quality of life, dyspnea severity, and fatigue level. However, there was limited evidence for respiratory, and peripheral muscle strength for CTD-ILD patients.
conclusionsThe literature shows that the use of PR for CTD-ILDs wasn't widespread. Our findings suggest that PR can be used in CTD-ILDs to recover clinical parameters like, lung functions, quality of life, dyspnea severity, and fatigue level. More comprehensive studies should be conducted to reveal the effect of the PR in the evidence-based frame.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.